Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 11/2009

01.07.2009 | Adis Drug Profile

Budesonide/Formoterol Pressurized Metered-Dose Inhaler

In Chronic Obstructive Pulmonary Disease

verfasst von: Katherine A. Lyseng-Williamson

Erschienen in: Drugs | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

  • ▲ The corticosteroid budesonide and the rapid-onset, long-acting β2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients with chronic obstructive pulmonary disease (COPD).
  • ▲ Well designed 6- and 12-month clinical trials, twice-daily budesonide/formoterol pMDI 320μg/9μg effectively improved lung function in patients with moderate to very severe COPD.
  • ▲ The co-primary endpoints of adjusted mean morning predose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1 improved from baseline to a significantly greater extent with twice-daily budesonide/formoterol pMDI 320μg/9μg than with twice-daily placebo, budesonide pMDI 320 µg and formoterol dry powder inhaler 9 μg.
  • ▲ Budesonide/formoterol pMDI was also associated with improvements from baseline in other measures of lung function, COPD control (including the time to first COPD exacerbation in the 12-month trial), symptoms and health status. These improvements were significantly greater than those observed with placebo and, for some endpoints, monotherapy with the individual components.
  • ▲ Budesonide/formoterol pMDI was well tolerated in clinical trials in patients with COPD. Its overall adverse event profile is consistent with the known tolerability profiles of formoterol and budesonide, and is generally similar to that with placebo.
Literatur
1.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2008) [online]. Available from URL: http://​www.​goldcopd.​com [Accessed 2009 Apr 21]
2.
Morbidity and mortality: 2007 chart book on cardiovascular, lung, and blood diseases. Bethesda (MD): National Heart, Lung, and Blood Institute, 2007
3.
Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med 2007 Aug; 120 (8 Suppl. 1): S4–13PubMedCrossRef
4.
Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD: a systematic review. Chest 2008 May; 133(5): 1079–87PubMedCrossRef
5.
Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 Nov 26; 300(20): 2407–16PubMedCrossRef
6.
Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007 Apr 18; (2): CD002991
7.
Paul Man S, Sin DD. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005; 65(5): 579–91CrossRef
8.
Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007 Oct 17; (4): CD006829
9.
Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007 Oct 17; (4): CD006826
10.
Eklund A, Tronde A, Johannes-Hellberg I, et al. Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm Drug Dispos 2008 Oct; 29(7): 382–95PubMedCrossRef
11.
Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol: US prescribing information. Wilmington (DE): AstraZeneca LP, 2009 Feb
12.
Lyseng-Williamson KA, Simpson D. Budesonide/ formoterol pressurized metered-dose inhaler. Drugs 2008; 68(13): 1855–64PubMedCrossRef
13.
Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007; 12(5): 732–9PubMedCrossRef
14.
Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68(14): 1975–2000PubMedCrossRef
15.
Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease. Drugs 2009; 69(5): 549–65PubMedCrossRef
16.
Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Resp J 2002 Jan; 19(1): 182–91CrossRef
17.
Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999 Oct; 104 (4 Pt 2): S175–83CrossRef
18.
Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Jul; 42(1): 115–37PubMedCrossRef
19.
Reynolds NA, Perry CM, Keating GM. Budesonide/ formoterol in chronic obstructive pulmonary disease. Drugs 2004; 64(4): 431–41PubMedCrossRef
20.
Lal H, Jansson AH, Falk-Hakansson H, et al. Intratracheal administration of combined budesonide and formoterol attenuates inflammation markers in a rat acute LPS model [abstract]. Am J Respir Crit Care Med 2008 Apr; 177 (Abstr. Suppl.): A105
21.
Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004; 27(10): 689–715PubMedCrossRef
22.
Bonay M, Bancal C, Crestani B. Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease. Drug Saf 2002; 25(1): 57–71PubMedCrossRef
23.
Tronde A, Gillen M, Borgstrom L, et al. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol 2008 Nov; 48(11): 1300–8PubMedCrossRef
24.
Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009 Feb 9; 169(3): 219–29PubMedCrossRef
Metadaten
Titel
Budesonide/Formoterol Pressurized Metered-Dose Inhaler
In Chronic Obstructive Pulmonary Disease
verfasst von
Katherine A. Lyseng-Williamson
Publikationsdatum
01.07.2009
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 11/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200969110-00005

Weitere Artikel der Ausgabe 11/2009

Drugs 11/2009 Zur Ausgabe

Therapy in Practice

Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-α Inhibitor Therapy

Adis Drug Profile

Ixabepilone

Original Research Article

Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens

Original Research Article

Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the US

Adis Drug Evaluation

Rabbit Antithymocyte Globulin (Thymoglobulin®)

Adis Drug Evaluation

Etoricoxib